Country: Evrópusambandið
Tungumál: enska
Heimild: EMA (European Medicines Agency)
grapiprant
Elanco GmbH
QM01AX92
grapiprant
Dogs
Other antiinflammatory and antirheumatic agents, non-steroids
For the treatment of pain associated with mild to moderate osteoarthritis in dogs.
Revision: 5
Authorised
2018-01-09
16 B. PACKAGE LEAFLET 17 PACKAGE LEAFLET: GALLIPRANT 20 MG TABLETS FOR DOGS GALLIPRANT 60 MG TABLETS FOR DOGS GALLIPRANT 100 MG TABLETS FOR DOGS 1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT Marketing authorisation holder: Elanco GmbH Heinz-Lohmann-Str. 4 27472 Cuxhaven Germany Manufacturer responsible for batch release: Elanco France S.A.S. 26 Rue de la Chapelle 68330 Huningue France 2. NAME OF THE VETERINARY MEDICINAL PRODUCT Galliprant 20 mg tablets for dogs Galliprant 60 mg tablets for dogs Galliprant 100 mg tablets for dogs grapiprant 3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENTS One tablet contains: ACTIVE SUBSTANCE: Grapiprant 20 mg Grapiprant 60 mg Grapiprant 100 mg 20 mg tablet: A brown speckled, biconvex oval tablet with a score on one face separating the debossed number ‘20’ on one half and the letters ‘MG’ on the other half; the letter ‘G’ is debossed on the other face. The tablet can be divided into equal halves. 60 mg tablet: A brown speckled, biconvex oval tablet with a score on one face separating the debossed number ‘60’ on one half and the letters ‘MG’ on the other half; the letter ‘G’ is debossed on the other face. The tablet can be divided into equal halves. 100 mg tablet: A brown speckled, biconvex oval tablet with the debossed number ‘100’ on one half and the letters ‘MG’ on the other half; the letter ‘G’ is debossed on the other face. 4. INDICATION(S) 18 For the treatment of pain associated with mild to moderate osteoarthritis in dogs. 5. CONTRAINDICATIONS Do not use in case of hypersensitivity to the active substance or any of the excipients. Do not use in pregnant, lactating or breeding animals. 6. ADVERSE REACTIONS Vomiting was observed very commonly in clinical studies. Soft-formed faeces, diarrhoea and inappetence were commonly observed in clinical studies. These signs were generally transient. Elevated liver enzymes, elevated BUN, el Lestu allt skjalið
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Galliprant 20 mg tablets for dogs Galliprant 60 mg tablets for dogs Galliprant 100 mg tablets for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: ACTIVE SUBSTANCE: Grapiprant 20 mg Grapiprant 60 mg Grapiprant 100 mg For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM 20 mg tablet: A brown speckled, biconvex oval tablet with a score on one face separating the debossed number ‘20’ on one half and the letters ‘MG’ on the other half; the letter ‘G’ is debossed on the other face. The tablet can be divided into equal halves. 60 mg tablet: A brown speckled, biconvex oval tablet with a score on one face separating the debossed number ‘60’ on one half and the letters ‘MG’ on the other half; the letter ‘G’ is debossed on the other face. The tablet can be divided into equal halves. 100 mg tablet: A brown speckled, biconvex oval tablet with the debossed number ‘100’ on one half and the letters ‘MG’ on the other half; the letter ‘G’ is debossed on the other face. 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Dogs. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES For the treatment of pain associated with mild to moderate osteoarthritis in dogs. 4.3 CONTRAINDICATIONS Do not use in case of hypersensitivity to the active substance or any of the excipients. Do not use in pregnant, lactating or breeding animals. See section 4.7. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES The majority of clinical cases assessed in the clinical field studies suffered from mild to moderate osteoarthritis based on the veterinary assessment. To achieve a substantiated response to treatment, use the veterinary medicinal product only in mild and moderate cases of osteoarthritis. From the two clinical field studies, the overall success rates based on CBPI (Canine Brief Pain Inventory, as completed by the owner) at 28 days after the start of the treatment, were 51.3% 3 (120/235) for G Lestu allt skjalið